Sugi Predict

Sugi Predict / Compounds / SCHEMBL274235

SCHEMBL274235

SCHEMBL274235

CNc1nccc(Oc2ccc3c(c2)OCN3C(=O)Nc2ccc(Cl)c(C(F)(F)F)c2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 9/20 0.51
▸ BRAF P15056 7/20 0.48
▸ MAPK14 Q16539 3/20 0.48
▸ TNNI3K Q59H18 2/20 0.48
▸ CDK8 P49336 4/20 0.47
▸ CCNC P24863 3/20 0.46
▸ RAF1 P04049 6/20 0.46
▸ RET P07949 3/20 0.46
▸ RIPK2 O43353 2/20 0.46
▸ ABCB11 O95342 2/20 0.46
▸ ABL1 P00519 2/20 0.46
▸ HTR1A P08908 2/20 0.46
▸ PDGFRB P09619 2/20 0.46
▸ ADORA3 P0DMS8 2/20 0.46
▸ KIT P10721 2/20 0.46
▸ FGFR1 P11362 2/20 0.46
▸ PDGFRA P16234 2/20 0.46
▸ FLT1 P17948 2/20 0.46
▸ MAOA P21397 2/20 0.46
▸ EPHA1 P21709 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL273466 0.91 KDR (0.54) KDRBRAFMAPK14TNNI3KCDK8
SCHEMBL2434370 0.80 KDR (0.59) KDRBRAFCDK8RETPDGFRB
SCHEMBL3595725 0.79 KDR (0.49) KDRBRAFMAPK14TNNI3KTEK
SCHEMBL2435232 0.77 KDR (0.54) KDRTEKLCKMET
SCHEMBL273501 0.77 TRPV1 (0.52) KDRMEN1KMT2A
SCHEMBL2434309 0.77 KDR (0.50) KDRBRAFRAF1FLT1MAPK3
SCHEMBL2434058 0.76 KDR (0.53) KDRTEKLCKMET
SCHEMBL274088 0.76 GRIN2B (0.47) KDRBRAFMAPK14FGFR1MEN1
SCHEMBL2434130 0.75 KDR (0.45) KDRBRAFCDK8FLT1FLT4
SCHEMBL2748395 0.75 KDR (0.75) KDRBRAFMAPK14TNNI3KRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133886-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2012-03-13 — — US claimed
US-20120122857-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2012-05-17 — — US disclosed
US-20120122857-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2012-05-17 — — US disclosed
US-8133886-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2012-03-13 — — US disclosed
US-8133886-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2012-03-13 — — US disclosed
US-8133886-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2012-03-13 — — US disclosed
EP-2371822-A1 Heterobicyclic carboxamides as inhibitors for kinases Novartis AG (CH) 2011-10-05 — — EP disclosed
US-20100029626-A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers NOVARTIS AG (CH) 2010-02-04 — — US disclosed
US-20100029626-A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers NOVARTIS AG (CH) 2010-02-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029626-A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers SLC8B1, MCU, GLS KDR 3083/4885BRAF 1039/4885MAPK14 765/4885
US-20120122857-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES MAP3K20, PHKG1, PHKG2 KDR 1319/4885BRAF 27/4885MAPK14 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.